{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:43:10Z","timestamp":1794040990455,"version":"4.8.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI155838, K23AI125720"],"award-info":[{"award-number":["K23AI155838, K23AI125720"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Extensive <jats:italic>Plasmodium falciparum<\/jats:italic> genetic diversity plays a role in immune evasion, and antibody responses can be strain-specific or broadly reactive depending on the epitope. Controlled human malaria infection (CHMI) allows investigation of immune responses to variant parasite proteins after a single infection with a known strain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We designed a novel diversity-reflecting peptide microarray containing 638,817 unique peptides representing 22,655 variants of 227 proteins from 23 P<jats:italic>. falciparum<\/jats:italic> genome assemblies and 379 field isolates. Using this array, we probed sera from 38 malaria na\u00efve adults before and 28 days after CHMI with one of two genetically distinct <jats:italic>P. falciparum<\/jats:italic> strains, NF54 (n = 21) or 7G8 (n = 17). We examined fold-increase in antibody response (intensity) and cross-reactivity to protein variants (breadth). ABCPred was used to predict linear epitopes for all 227 proteins. We used MEME to identify enriched motifs in regions of high intensity or breadth, which were presumed to be potential epitopes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>While the two CHMI groups had similar intensity of responses to all proteins on the array, 20 proteins on the array had differential breadth of responses and participants infected with 7G8 strain had a higher breadth of responses to 17 of them. Of 543 ABCPred-predicted epitopes, 66 overlapped with MEME-identified epitopes, six of which were highly cross-reactive with &amp;gt;95% of peptide variants serorecognized by at least one CHMI group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Overall, we found most antibody responses to be comparable after infection with the NF54 strain or 7G8 strain, but we saw notable differences for ~10% of proteins on the array. While many MEME-identified epitopes from highly cross-reactive proteins were asparagine rich, an epitope from PF3D7_1033200 (ETRAMP10.2) was not. Highly cross-reactive responses to ETRAMP10.2 could be further characterized and ETRAMP10.2 could be considered for inclusion in a next generation vaccine.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1641280","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:29:27Z","timestamp":1757914167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides"],"prefix":"10.3389","volume":"16","author":[{"given":"DeAnna J.","family":"Friedman-Klabanoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis L.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten E.","family":"Lyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana C.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Stucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amed","family":"Ouattara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olukemi O.","family":"Ifeonu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara A.","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey E.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes B.","family":"Goll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigar J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Pinapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Deye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Takala-Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Travassos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","volume-title":"World malaria report 2024: addressing inequity in the global malaria response","year":"2024"},{"key":"B2","volume-title":"WHO recommends groundbreaking malaria vaccine for children at risk","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S0140-6736(21)02237-6","article-title":"Cautious optimism for malaria vaccine roll-out","volume":"398","author":"Samarasekera","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-04343-7","article-title":"The slow roll-out of the world\u2019s first malaria vaccine","volume":"612","author":"Willyard","year":"2022","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","year":"2014","journal-title":"PloS Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"B7","unstructured":"WHO recommends R21\/Matrix-M vaccine for malaria prevention in updated advice on immunization\n          \n          \n          \n          2023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B10","volume-title":"Malaria vaccines: preferred product characteristics and clinical development considerations","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.142","article-title":"Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research","volume":"23","author":"Heppner","year":"2005","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature01097","article-title":"Genome sequence of the human malaria parasite Plasmodium falciparum","volume":"419","author":"Gardner","year":"2002","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.3299709","article-title":"Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications","volume":"237","author":"Hoffman","year":"1987","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4513","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","volume":"24","author":"Tan","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1125785","article-title":"Polymorphism in liver-stage malaria vaccine candidate proteins: immune evasion and implications for vaccine design","volume":"15","author":"Flanagan","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1996.88","article-title":"Antigenic variation and immune evasion in Plasmodium falciparum malaria","volume":"74","author":"Reeder","year":"1996","journal-title":"Immunol Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.11.6.987-995.2004","article-title":"Antigenic diversity and immune evasion by malaria parasites","volume":"11","author":"Ferreira","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200800194","article-title":"Profiling humoral immune responses to P. falciparum infection with protein microarrays","volume":"8","author":"Doolan","year":"2008","journal-title":"Proteomics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"M111 007948","DOI":"10.1074\/mcp.M111.007948","article-title":"Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens","volume":"10","author":"Trieu","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/srep03549","article-title":"Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis","volume":"3","author":"Felgner","year":"2013","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv224","article-title":"Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya","volume":"212","author":"Dent","year":"2015","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101783","article-title":"Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications","volume":"9","author":"Gandhi","year":"2014","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.035","article-title":"Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1\/AS02(A) vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants","volume":"38","author":"Ouattara","year":"2020","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/microorganisms10061090","article-title":"An in silico analysis of malaria pre-erythrocytic-stage antigens interpreting worldwide genetic data to suggest vaccine candidate variants and epitopes","volume":"10","author":"Ouattara","year":"2022","journal-title":"Microorganisms"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1038\/s41598-020-60551-z","article-title":"Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination","volume":"10","author":"Bailey","year":"2020","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4269\/ajtmh.14-0140","article-title":"Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria","volume":"92","author":"Bailey","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3024.2009.01138.x","article-title":"Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming \u2018vaccine resistant malaria\u2019","volume":"31","author":"Takala","year":"2009","journal-title":"Parasite Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2ra5","DOI":"10.1126\/scitranslmed.3000257","article-title":"Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development","volume":"1","author":"Takala","year":"2009","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701464104","article-title":"Structural basis of antigenic escape of a malaria vaccine candidate","volume":"104","author":"Dutta","year":"2007","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis709","article-title":"Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications","volume":"207","author":"Ouattara","year":"2013","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0708-9","article-title":"Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential","volume":"12","author":"Moser","year":"2020","journal-title":"Genome Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0341","article-title":"Optimizing intradermal administration of cryopreserved plasmodium falciparum sporozoites in controlled human malaria infection","volume":"93","author":"Lyke","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz410","article-title":"Dose-dependent infectivity of aseptic, purified, cryopreserved plasmodium falciparum 7G8 sporozoites in malaria-naive adults","volume":"220","author":"Laurens","year":"2019","journal-title":"J Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix334","article-title":"Association of a novel mutation in the plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity","volume":"216","author":"Agrawal","year":"2017","journal-title":"J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309390110","article-title":"Immunosignatures can predict vaccine efficacy","volume":"110","author":"Legutki","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2013.06.001","article-title":"A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling","volume":"395","author":"Imholte","year":"2013","journal-title":"J Immunol Methods"},{"key":"B40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/0-387-29362-0_23","article-title":"Limma: linear models for microarray data","volume-title":"Bioinformatics and computational biology solutions using R and Bioconductor","author":"Smyth","year":"2005"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp335","article-title":"MEME SUITE: tools for motif discovery and searching","volume":"37","author":"Bailey","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"R24","DOI":"10.1186\/gb-2007-8-2-r24","article-title":"Quantifying similarity between motifs","volume":"8","author":"Gupta","year":"2007","journal-title":"Genome Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2174\/0929866511320060011","article-title":"Evaluation and comparison of the ability of online available prediction programs to predict true linear B-cell epitopes","volume":"20","author":"Costa","year":"2013","journal-title":"Protein Pept Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0476","article-title":"The controlled human malaria infection experience at the university of maryland","volume":"100","author":"Friedman-Klabanoff","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fux046","article-title":"Repetitive sequences in malaria parasite proteins","volume":"41","author":"Davies","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/0166-6851(90)90085-z","article-title":"Cross-reactive asparagine-rich determinants shared between several blood-stage antigens of Plasmodium falciparum and the circumsporozoite protein","volume":"40","author":"Ardeshir","year":"1990","journal-title":"Mol Biochem Parasitol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81401","article-title":"Antibodies to repeat-containing antigens in Plasmodium falciparum are exposure-dependent and short-lived in children in natural malaria infections","volume":"12","author":"Raghavan","year":"2023","journal-title":"Elife"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2024.1424202","article-title":"PhIP-Seq: methods, applications and challenges","volume":"4","author":"Huang","year":"2024","journal-title":"Front Bioinform"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.030","article-title":"High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya","volume":"24","author":"Polley","year":"2006","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-3024.1995.tb00920.x","article-title":"Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria","volume":"17","author":"al-Yaman","year":"1995","journal-title":"Parasite Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3024.2003.00636.x","article-title":"Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria","volume":"25","author":"Metzger","year":"2003","journal-title":"Parasite Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1998.58.406","article-title":"IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria","volume":"58","author":"Taylor","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01585-07","article-title":"Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria","volume":"76","author":"Osier","year":"2008","journal-title":"Infect Immun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000218","article-title":"The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis","volume":"7","author":"Fowkes","year":"2010","journal-title":"PLoS Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exppara.2006.05.003","article-title":"Plasmodium falciparum: worldwide sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-2 (MSP-2)","volume":"115","author":"Ferreira","year":"2007","journal-title":"Exp Parasitol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2017.02.003","article-title":"Structure and characterisation of a key epitope in the conserved C-terminal domain of the malaria vaccine candidate MSP2","volume":"429","author":"Seow","year":"2017","journal-title":"J Mol Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e02-04-0240","article-title":"etramps, a new Plasmodium falciparum gene family coding for developmentally regulated and highly charged membrane proteins located at the parasite-host cell interface","volume":"14","author":"Spielmann","year":"2003","journal-title":"Mol Biol Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.009","article-title":"Synthetic peptides from conserved regions of the Plasmodium falciparum early transcribed membrane and ring exported proteins bind specifically to red blood cell proteins","volume":"27","author":"Garcia","year":"2009","journal-title":"Vaccine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001323107","article-title":"A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray","volume":"107","author":"Crompton","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","article-title":"Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy","volume":"10","author":"Dobano","year":"2019","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T05:29:31Z","timestamp":1757914171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2025.1641280"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1641280","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1641280"}}